ID: ALA4087909

Max Phase: Preclinical

Molecular Formula: C18H15N3O3

Molecular Weight: 321.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-n2nc3c4ccc(OC)cc4[nH]cc-3c2=O)cc1

Standard InChI:  InChI=1S/C18H15N3O3/c1-23-12-5-3-11(4-6-12)21-18(22)15-10-19-16-9-13(24-2)7-8-14(16)17(15)20-21/h3-10,19H,1-2H3

Standard InChI Key:  IPYGULVOAIXELM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 321.34

Molecular Weight (Monoisotopic): 321.1113

AlogP: 2.84

#Rotatable Bonds: 3

Polar Surface Area: 69.14

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 11.62

CX Basic pKa: 2.02

CX LogP: 2.10

CX LogD: 2.10

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.63

Np Likeness Score: -0.86

References

1. Knutson DE, Kodali R, Divović B, Treven M, Stephen MR, Zahn NM, Dobričić V, Huber AT, Meirelles MA, Verma RS, Wimmer L, Witzigmann C, Arnold LA, Chiou LC, Ernst M, Mihovilovic MD, Savić MM, Sieghart W, Cook JM..  (2018)  Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability.,  61  (6): [PMID:29481759] [10.1021/acs.jmedchem.7b01664]

2. Simeone X, Iorio MT, Siebert DCB, Rehman S, Schnürch M, Mihovilovic MD, Ernst M..  (2019)  Defined concatenated α6α1β3γ2 GABA_A receptor constructs reveal dual action of pyrazoloquinolinone allosteric modulators.,  27  (14): [PMID:31186146] [10.1016/j.bmc.2019.06.006]

Source

Source(1):

• Scientific Literature